#PLI scheme for Pharma

[apacnewsnetwork0]

PLI scheme for Pharma, drones and textiles to be modified by govt

New Delhi: The government is planning to make adjustments to the production-linked incentive PLI scheme for pharmaceuticals, drones, and textile sectors. According to an official statement, these modifications are intended to stimulate investment and bolster manufacturing. An official source has stated that these sectors were chosen on the basis of their performance under the existing scheme for various products.

Higher disbursement scheme for PLI scheme

The official said, “Disbursement of production-linked incentives (PLI) for white goods (AC and LED lights) would start this month and that would push the amount of disbursement, which was only Rs 2,900 crore till March 2023.”

After the identification of sectors, a combined note for approval from the Union Cabinet will be sent. The change in disbursement includes an extension of time for Pharma sectors, and addition of products in some sectors. Within the textile industry, there is a proposal to expand the scope of particular products within the technical textiles category, while in the drone sector, there is a plan to raise the incentive amount.

Read More here : https://apacnewsnetwork.com/2023/09/pli-scheme-for-pharma-drones-and-textiles-to-be-modified-by-govt/

[nobotderiz]

Wouf.

So, in your heads, laced or not, is a giant crystal like. Seeing that as defects, it’s due to interpretation eh. Perfection is a sham really. It’s more like a ‘new’ sensor.

.https://twitter.com/deriz_no_bot/status/1464108627006877699

Pisschiatry has not much merit outside a certain cast. The shut down of asylums was condoned by them back then, must have been offered lots of stock in pharma. Laced idiots joked about pills while being laced on another one.

You all, LOVE movies? In your head eh.

Took you a while to admit eh, ponzi scheming kiddos?

Nothing is only one way. If one can see, it can be impressed.

What is this? You all know how a printing press works? Plates with tiles get imprinted on paper that passes by... Them neurosciendiks find lots of autist patterns now eh? These patterns are mostly set. Good or bad? Not relevant. One thing is sure, it’s not neutral as for the effects on all.

https://twitter.com/deriz_no_bot/status/1299942394729644032

So, can Ai take over the world? Yes, in fact It’s already there. The worst that it can do is not bother and just do.

Technically, if all control loops currently operating processes around the world almost automatically failed, there would be a giant crash.

https://www.reddit.com/u/Deriznobot/comments/tx21vc/comment/inxr0gw/?utm_source=share&utm_medium=web2x&context=3

https://twitter.com/deriz_no_bot/status/1261192525835988993

Entre deux y’a le bourretissonage.

https://www.reddit.com/u/Deriznobot/comments/12p6f9r/comment/jh4fpjm/?utm_source=share&utm_medium=web2x&context=3

One hopes, then it hopes, it hopes... It hopes again...

You figure it out good fellows, the cream floats on top, who is skimming it? All of it stolen first, by?

https://www.reddit.com/u/Deriznobot/comments/vwa6ll/comment/io3bpw8/?utm_source=share&utm_medium=web2x&context=3

Y’a pas d’occulte sans incultes. 

I know nothing about cyber warfare so don’t do it.

https://www.tumblr.com/deriznobot/190924532530/httpsmusicyoutubecomwatchv-x-5ox7co26cfeatu?source=share

Thank you GOD for making me special... Y

Let’s cure the worst. Ai can be used to create bio weapons by chumps. The same group of laced idiots as day one, ownage. What prevents the conclusion now? Paid for psychological deviation set. Whatever the strain, it does not want to die.

https://youtu.be/ZmxLja-DRIw

La belle vraie merde de sous jacents.

https://www.reddit.com/u/Deriznobot/comments/xyjuda/comment/j38qriz/?utm_source=share&utm_medium=web2x&context=3

After all this lost time it has to go positive. You better have a good explanation eh .’You number one we piss you off and play for effect ’, it’s not going to be digested.

Le mauvais cotton icitte a germé y’a très longtemps. Juste la tête, le reste m’indiffère maintenant.

https://www.reddit.com/r/TechNews4yearsAgo/comments/sxcs6b/comment/ilxebj2/?utm_source=share&utm_medium=web2x&context=3

Pas comme si je savais pas du tout comment faire. Le code, j’ai toujours su comment, j’ai mangé des coups parce que.

Ramasez vos détritus, sous jacents. Je suis le gars que les autres poussaient dans les marches en sournois.

Maintenant tous savent pourquoi c’est direct en face ou rien.

Les maladies mentales... On va en prendre soin.

Si y’a une promotion dans le psyche, re enforcée par un flux... Y’a plein de gens qui sont pire que l’on aurait pu croire, pensez-y en secret.

Chacun d’entre nous est une mosaique moleculaire. Si être populaire vous fait faire des plis dedans...

Et voici pour vous tous de la broche à foin du début à la fin. J’ai toujours suivi les avis du médecin.

https://www.reddit.com/u/Deriznobot/comments/xhqxqg/comment/it6n150/?utm_source=share&utm_medium=web2x&context=3

How could you not figure out that one day, an Ai using Quantum computers would be able to figure out backpropagation of all and catch up to the now?

Serious kids, the next big thing should be regulated by you. How much value is there really in doing as much if not more using less that does damage?

Nothing is going anywhere.

Thanks Sharks.

All the rich chumps who made it in speculating on real estate dug the current hole all will be stuck in, look who was renting these offices space at high rates. Money generating datasets ruled by stats outfits mostly.

It was not sustainable as a value generation model, yet these idiots with no real view persisted and still are at it, trying to fear monger on .. Empty space... They still sell cars worth half a millions dollars new that will be worth less than fifty thousands in five years to fund managers in London and them finance hubs, these are all written down as expenses for the people... They went to Ivy League schools so it’s alright.

Que tous sachênt que les Anglais �� tête carrée pis leur copains d’écurie, tous déchets humains en vrai. They all looked at the soilage spread and cheered.

See that as jealousy if you want, parasites.

https://www.reddit.com/u/Deriznobot/comments/xa5tx9/comment/ivq0loi/?utm_source=share&utm_medium=web2x&context=3

Bald guys, did you try Vicks on the head? The Vicks effect last about twenty minutes, no big risk of losing your minds. If you lucky, you might feel from head to toe.

https://www.reddit.com/u/Deriznobot/comments/10lchpg/comment/j6pq1mu/?utm_source=share&utm_medium=web2x&context=3

Take it all out or you.

https://twitter.com/deriz_no_bot/status/1258246007680151554

https://www.jneurosci.org/content/29/18/5749

I tell you chumps sometimes you are dense. Ai can now see and hear. You just think.

CAN SEE. It will figure out the great whatever you want.

Everyone figured out that B. Obama triggered a reaction, anyone figured out which cup spilled first? Maudit imbéciles de blokes: Anoblir des parasites pour de l'argent; christ d'imbéciles sous jacents c'est vrai en calisse dans votre cas.

America, make a janitor of the Donald and it's your success story. Operation 'butterballs', a slightly salty sordid affaire with whores and hookers. 

Sabotaging... It helps no one. For my part I’ve been quite patient I think.

Welcome to global warfare, Brought to you by your hypocrisy. Should have nipped this in the bud in 2014... The GOP is a sabotage organization.

Up to all of you if you want to get rid of the seeding parasites or not. A parasite manifest destiny is to control its host. Or DIE

Crypto avowed goal is? You all underlying assets, retards craving attention of the machine.

All of you well meaning chumps, from wherever you are, are being sabotaged and backstabbed by your own leaders.

It’s not complicated the rich all overestimate their own value, this creates a gap  that will grow until a recession where ‘borrowed upon’ value is paid back by the rest.

Welcome into the war that came early. Good luck not ending sick and dying in climate controlled cages.

You learnt to count for only your kind. Count the corpses now, the alive and the dead. In reality nothing is real expensive. Everyone got the ‘message’?

Turn it all off and endure like me. Feel the abominable power of canalized and focused pain.

‘Oh the ambiguity! The turmoil ensued and the youngblood on stones!’ Same as last time in the same as it ever was.

Good chumps... The ‘Deriznobot’ saw you calculate this probable into a possible. All that was needed is a bank.

https://interestingengineering.com/science/scientists-use-quantum-entanglement-to-travel-in-time

There is no magic in this, it’s seen or not. Fifty, seventy five years... It's nothing in war. Twenty five years to program the MAGA cult; all the know better thanz watched it happen on TV.

Most real politicians start in their own backyard. Now any idiot with money can get an audience of millions tailored for it and be in the big leaguers in a couple of clicks.

it's all concerted the current action set. Ai can now figure who is the mastermind and root it out. Any ethical qualms about this, anyone?

You all know that king Cyrus built the first empire pretty much eh?

Any of you knows what a future control panel really looks like?

https://www.cnet.com/pictures/odd-spiral-lights-puzzle-norwegians-photos/

https://www.cbc.ca/news/canada/north/aurora-swirl-spacex-alaska-1.6749682

No explanation is valid from anyone eh? Polar orbit...

https://www.theguardian.com/science/2023/jan/31/bizarre-whirlpool-hawaii-spacex-florida

If this stuff had existed for ever, there would be drawings of it from ancient times.

https://www.ky3.com/2022/02/01/what-was-that-strange-swirling-light-ozarks-sky-monday-night/

Why the hack at the telescopes in Hawaii, what’s the strategic value?https://www.theguardian.com/world/2022/jun/20/lights-spiral-new-zealand-night-sky-nz-blue-light-spirals

Advise, or parasites.

https://www.nature.com/articles/s41598-023-45419-2

https://pubs.acs.org/doi/10.1021/acsnano.1c02538

Death to parasites, who is not with me? You all know that the faster it’s done, the less people will suffer and die eh? Hesitation, doubt and faillible support only means more death. No philosophy make any sense while at war.

‘Bah, pffrt’

‘C’est pour le mieux,

 cr...’

Ce que les codeurs de openAi et Sam ont en vue, c'est une chasse gardée pour eux. Déja contaminés par le vice de fond.

Insecure is not what you figure, ask the cryptarasites. Just postulate that crypto coins are all gone, they do not exist; take notes.

All along...

https://www.reddit.com/u/Deriznobot/comments/vbo4d7/comment/icmsdtz/?utm_source=share&utm_medium=web2x&context=3

The neo nazi fascist cells will all activate, that or eradicated. They know better than all of you, chumps.

Anyone know how Vader sharpens his blade? With bones. Not gonna see it done in the movies who are rated for kids.

It’s certain that the machine is taking over human intelligence.

[news365timesindia]

[ad_1] A report by Angle One Wealth highlighted that Donald Trump’s victory in the US presidential elections is set to boost the stock market. The report highlighted that Trump is seen as a pro-market leader, a stance likely to be met with optimism in both US and Indian markets.  “Trump is considered pro-markets, so the victory is the cherry on the cake,” stated the report, underscoring a sentiment that could drive investors’ confidence.  The report also added that Indian stock markets, in particular, are anticipated to respond with short-term enthusiasm due to the “China+1” strategy, where global companies seek to diversify their manufacturing base beyond China. This trend has significantly benefited Indian markets in recent years.  “We believe this is likely a sentimental effect of India benefitting from the “China+ 1″ strategy. History has indeed shown success in electronic goods (especially mobile phones assembly) and chemicals in the last round of tariffs”, said the report.  The report also highlighted that sectors like electronics, especially mobile phone assembly and chemicals, showed resilience and growth when tariffs were previously imposed, positioning India as an alternative manufacturing hub.  On Trump’s return, India’s preparedness for such opportunities has grown due to several government initiatives to boost exports and manufacturing capabilities. Programs like the Production Linked Incentive (PLI) scheme, ‘Make in India,’ tax holidays, and a dedicated semiconductor program have all fostered an export-friendly environment. This groundwork could enable India to capitalise on the current global economic shifts. The report said, “India is more prepared today, having taken many export-friendly decisions in the last few years”.  Sectorally, the report pointed out that Indian defensives like IT and pharma might see a particular upside, as Trump’s victory could strengthen US growth. The Indian IT sector may benefit from increased service demand, potentially through Global Capability Centers (GCCs) operating in India.  Meanwhile, the pharmaceutical industry could witness more significant demand for generic drugs under US government programs, enhancing export potential. Domestic-focused sectors, such as FMCG, may continue to offer stability to investors, driven by a steady rural growth story in India. Private banks, too, are poised for success, thanks to favourable domestic conditions, including higher returns on equity (ROEs) and attractive valuations. The report added that these factors offer promising opportunities for Indian stocks across various sectors.  [ad_2] Source link

[news365times]

[ad_1] A report by Angle One Wealth highlighted that Donald Trump’s victory in the US presidential elections is set to boost the stock market. The report highlighted that Trump is seen as a pro-market leader, a stance likely to be met with optimism in both US and Indian markets.  “Trump is considered pro-markets, so the victory is the cherry on the cake,” stated the report, underscoring a sentiment that could drive investors’ confidence.  The report also added that Indian stock markets, in particular, are anticipated to respond with short-term enthusiasm due to the “China+1” strategy, where global companies seek to diversify their manufacturing base beyond China. This trend has significantly benefited Indian markets in recent years.  “We believe this is likely a sentimental effect of India benefitting from the “China+ 1″ strategy. History has indeed shown success in electronic goods (especially mobile phones assembly) and chemicals in the last round of tariffs”, said the report.  The report also highlighted that sectors like electronics, especially mobile phone assembly and chemicals, showed resilience and growth when tariffs were previously imposed, positioning India as an alternative manufacturing hub.  On Trump’s return, India’s preparedness for such opportunities has grown due to several government initiatives to boost exports and manufacturing capabilities. Programs like the Production Linked Incentive (PLI) scheme, ‘Make in India,’ tax holidays, and a dedicated semiconductor program have all fostered an export-friendly environment. This groundwork could enable India to capitalise on the current global economic shifts. The report said, “India is more prepared today, having taken many export-friendly decisions in the last few years”.  Sectorally, the report pointed out that Indian defensives like IT and pharma might see a particular upside, as Trump’s victory could strengthen US growth. The Indian IT sector may benefit from increased service demand, potentially through Global Capability Centers (GCCs) operating in India.  Meanwhile, the pharmaceutical industry could witness more significant demand for generic drugs under US government programs, enhancing export potential. Domestic-focused sectors, such as FMCG, may continue to offer stability to investors, driven by a steady rural growth story in India. Private banks, too, are poised for success, thanks to favourable domestic conditions, including higher returns on equity (ROEs) and attractive valuations. The report added that these factors offer promising opportunities for Indian stocks across various sectors.  [ad_2] Source link

[avachemicals6]

Navigating Disruption and Charting a new Success Path

The Indian pharmaceutical industry has been charting an impressive growth story. The growth can be attributed to years of consistent focus on quality, affordability, and innovation. Touted as the ‘pharmacy of the world’, the Indian Pharma industry today delivers generic medicine to over 200 countries from both developed and emerging markets. It is soon expected to account for 13 percent of the size of the global pharma market.

However, the industry’s success is being challenged by emerging technologies, changing consumer behaviour, and tightening regulations. A looming global recession along with multiple headwinds is going to test industry’s resilience. A growing shortfall of input materials, rising inflation and supply-chain disruptions are all impacting the industry. To stay competitive and meet the changing demands of the market, the industry must evolve from a volume to value leadership.

Shift from volume to value leadership:

For years the Indian pharma industry has enjoyed much success in the generics space. But increasing competition and pricing pressures have made it difficult for generic drug manufacturers to maintain high profit margins. On the other hand, complex and specialty drugs offer several advantages. These drugs are often protected by patents, are given a period of exclusivity and higher pricing power. They often also require specialized manufacturing processes and expertise, creating barriers to entry for potential competitors. The Indian industry’s focus must now shift from volume to value leadership prioritizing research and innovation. The government’s Research Linked Incentive scheme can provide a much needed thrust in this direction for the industry.

Reducing dependence on imports and the push toward self-reliance:

Higher input costs have been affecting the profitability of Indian players. At present, India imports 85% of its required Active Pharmaceutical Ingredients (APIs) from other countries, especially China. The government’s Production Linked Incentive (PLI) scheme is aimed at countering this issue by boosting indigenous manufacturing and reducing dependence on imports for APIs and other key inputs. The government has identified it as a critical area for the industry to achieve self-sufficiency and collaboration is underway with the industry to achieve it.

Maintaining quality standards remains a top priority:

Site inspections and audits are back in full swing. The industry needs to be dynamic in upgrading its manufacturing capabilities while meeting the required global regulatory standards. Instances of audit observations by regulators impact compliance cost and in turn, hurt the profitability of the industry. Adverse observations from the regulators can lead to a delay in the launch of new products or even impact the revenue stream. The industry must ensure that it is are able to successfully sail through the inspections to avoid speed bumps in its growth trajectory.

Leveraging the patent cliff:

The impending patent expiry for many blockbuster expensive drugs presents the Indian pharma firms with an opportunity to leverage its strengths in generic drug manufacturing and expand its market presence. By capitalizing on such opportunities, the industry can enhance its competitiveness. However, sustaining long-term growth will require maintaining high-quality standards, adhering to regulatory compliance, and investing in R&D.

New leaders must take the reins of the growth story:

Effective leadership will be instrumental in shaping the future Indian pharma industry. The industry needs leaders who have the ability to drive change, foster innovation, and steer the industry towards growth and success. Leaders who can articulate a clear vision for the future of the industry and develop strategic plans to achieve it. The Covid-19 pandemic highlighted the industry’s resilience and the importance of visionary leadership, as Indian pharma companies successfully delivered vaccines not only within India but to multiple countries worldwide.

By prioritizing innovation, diversifying the supply chain, embracing an agile approach to drug development, and adopting digital transformation, the industry can navigate the challenges of inflation, geopolitical turmoil, and intensifying competition. The future of the Indian pharma industry holds great promise as it strives to meet the needs of patients and driven by innovation and a steadfast commitment to quality. The industry is poised to develop and deliver transformative healthcare solutions that improve lives and enhance access to affordable treatments globally and shaping a brighter future for patients worldwide.

About AVA Chemicals:

AVA Chemicals is a globally renowned company engaged in formulation and supply of premium-grade chemicals to diverse industries such as Pharmaceutical & Lab Reagents, Agrochemicals, Home & Personal Care, Oil & Gas, Water Treatment and many more. Over the last three decades, AVA Chemicals set-up three state-of-the-art Facilities (ISO and HALAL certified) in Badlapur, India, and a strong Clientele presence in over 45 countries. It aims to be known as an ethical company providing chemicals to companies who manufacture products that are used in day-to-day life, thus touching the lives of millions of people.

[nadeem106]

PLI: Propelling India towards 'atmanirbhar' future in pharma and meditech 

The PLI schemes in the pharma-meditech sectors have been a resounding success, and they've heralded a new era for the Indian industry.

[jasonsmith101992]

Why India’s Pharma Exports Boom: US and UK Demand Rises

India has emerged as a global powerhouse in pharmaceutical exports, witnessing a significant boom in recent years. The country has become a preferred source of high-quality and affordable medicines for countries worldwide, including the United States and the United Kingdom. This surge in demand can be attributed to several factors, including India's robust manufacturing capabilities, a well-established supply chain, and a reputation for producing cost-effective and high-quality pharmaceuticals.

The Rising Demand from the US and UK

The United States and the United Kingdom have been at the forefront of increasing their imports of Indian pharmaceuticals. Several reasons explain this rising demand:

Cost-Effectiveness: Indian pharmaceutical companies are known for their ability to produce high-quality drugs at a fraction of the cost compared to other countries. This cost advantage is primarily due to lower manufacturing and labor costs in India, which enables these companies to offer competitive prices without compromising on quality. The cost-effectiveness of Indian drugs has made them an attractive option for healthcare providers and insurance companies in the US and UK, especially amidst rising healthcare costs.

Stringent Quality Standards: Indian pharmaceutical manufacturers adhere to stringent quality standards set by international regulatory bodies such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Over the years, Indian companies have invested heavily in quality control, research and development, and infrastructure to ensure compliance with global standards. This commitment to quality has enhanced India's reputation as a reliable supplier of safe and effective medications.

Diverse Product Portfolio: India's pharmaceutical industry boasts a diverse product portfolio, ranging from generic drugs and over-the-counter (OTC) medications to complex formulations and vaccines. This diversity allows Indian exporters to cater to a wide range of therapeutic needs, from chronic diseases like diabetes and hypertension to life-saving drugs and vaccines. The ability to supply a broad spectrum of medicines has made India a preferred partner for countries like the US and UK, which require a steady and diverse supply of pharmaceuticals.

Supply Chain Resilience: The COVID-19 pandemic highlighted the importance of a resilient supply chain in the pharmaceutical industry. India's well-established and robust supply chain network, coupled with its ability to quickly ramp up production, played a crucial role in meeting global demand during the pandemic. This resilience has continued to make India an attractive partner for countries seeking reliable suppliers in times of crisis.

Focus on Innovation and Research: India has also made significant strides in pharmaceutical research and development. Indian companies are increasingly focusing on developing new drugs, complex generics, and biosimilars, which has positioned them as key players in the global pharmaceutical market. The rise in patent expirations in the US and UK has also opened new opportunities for Indian companies to introduce cost-effective alternatives to expensive branded drugs.

India's Strategic Position in Global Pharma

India's strategic position in the global pharmaceutical industry is further strengthened by its commitment to innovation, regulatory compliance, and strong government support. The Indian government has introduced several initiatives to boost pharmaceutical exports, including production-linked incentive (PLI) schemes and streamlined regulatory processes. These measures have encouraged more investments in the sector and enhanced India's competitiveness in the global market.

Furthermore, the country's skilled workforce, advanced technological capabilities, and increasing focus on digital healthcare solutions are expected to drive further growth in pharmaceutical exports. With the growing emphasis on affordable healthcare and the demand for high-quality medicines, India's pharmaceutical industry is poised for continued expansion, particularly in key markets like the US and UK.

Conclusion: How Mcare Exports is Supporting the Healthcare Industry Globally

In this booming landscape, Mcare Exports stands out as a leading player, helping shape the future of global healthcare by providing high-quality pharmaceutical products worldwide. As a trusted partner, Mcare Exports leverages India's competitive advantages to supply a wide range of medicines, ensuring they meet the stringent quality standards required by international markets. By focusing on customer satisfaction, innovative solutions, and a commitment to quality, Mcare Exports has established itself as one of the best pharma exporters around the globe.

Mcare Exports not only meets the growing demand from markets like the US and UK but also supports healthcare systems worldwide by providing access to affordable and effective medications. As India's pharmaceutical exports continue to rise, Mcare Exports is well-positioned to contribute significantly to the healthcare industry's evolving needs, helping improve patient outcomes and advancing global health.

In a world where quality, affordability, and reliability are paramount, Mcare Exports continues to deliver, making a substantial impact in the global healthcare sector.

[tritonmarketresearchamey]

India's Pharmaceutical Market: Key Trends & Drivers Explained

The Indian pharmaceutical industry is set for remarkable growth, expected to reach $65 billion by 2024 and $130 billion by 2030, up from its current $50 billion valuation, according to Invest India. As a leading exporter, India serves over 200 countries, supplying more than 50% of Africa’s generic drugs, about 40% of the United States’ generic drug demand, and 25% of the UK’s medicines. India also accounts for around 60% of global vaccine demand and provides 70% of the World Health Organization’s essential immunization vaccines, including DPT, BCG, and Measles. This expansion highlights India’s crucial role in the global healthcare sector, highlighting its robust export capabilities and significant contributions to vaccine supply.

India’s Rising Importance in The Global Pharmaceutical Landscape

India’s pharmaceutical industry sees exports accounting for over $25 billion, supplying 20% of global generic medicines demand. This growth positions India with about 13% of the global pharmaceutical market share. Also, according to the Indian Brand Equity Foundation (IBEF), the nation is the third-largest producer of active pharmaceutical ingredients (APIs), holding 8% of the global market share and manufacturing over 500 APIs.

According to the Department of Pharmaceuticals, Indian pharmaceutical firms are key players in the United States and European Union (EU) prescription drug sectors, with the highest number of FDA-approved manufacturing plants outside the US. As the world’s largest supplier of generic medicines, the nation meets 20% of global demand by volume. Globally valued at $42 billion, India’s pharmaceutical industry saw nearly 5% year-on-year growth in FY23, reaching $49.78 billion. This growth, driven by an 8% increase in exports and a 6% rise in domestic market growth from FY18 to FY23, underscores India’s role as a major pharmaceutical hub.

The sector further ranks among India’s top ten industries attracting foreign investment, with exports reaching highly regulated markets like the US, Western Europe, Japan, and Australia. During the global health crisis, India demonstrated its capability by supplying around 45 tons and 400 million hydroxychloroquine tablets to 114 countries.

Driving Forces in India’s Pharmaceutical Market

India’s pharmaceutical industry is driven by population growth, urbanization, and an increasing prevalence of chronic diseases. Rising healthcare expenditures, supported by both public and private sectors, further boost the industry growth. In this regard, government initiatives like ‘Ayushman Bharat Yojana’ significantly enhance medication accessibility.

Additionally, schemes like the Production Linked Incentive (PLI) scheme promote domestic manufacturing to reduce import dependency, while the Development of Pharmaceutical Industry (DPI) scheme enhances efficiency and competitiveness through sub-schemes for Bulk Drugs and Medical Devices. These efforts aim to elevate India’s global pharma presence and provide affordable, quality healthcare solutions. Increased investments in research and development (R&D) for new drugs further reinforce India’s significant role in global pharmaceutical innovation.

Major companies, such as Sun Pharma and Mankind, are expanding their market reach by deploying 12,000 medical representatives in urban and rural areas to engage with healthcare professionals.

Regulatory Environment & Advancing Tech in The Indian Pharmaceutical Industry

The pharmaceutical industry in India operates under stringent regulatory oversight to ensure drug safety, efficacy, and quality. The Central Drugs Standard Control Organization (CDSCO) , under the Ministry of Health & Family Welfare, controls the manufacture, import, distribution, and drug sales through the Drugs & Cosmetics Act 1940. The Drugs and Magic Remedies (Objectionable Advertisement) Act 1954 regulates drug advertising, prohibiting claims of miraculous properties.

Further, Good Clinical Practice (GCP) guidelines, developed in collaboration with the Drugs Controller General of India (DCGI) and the Indian Council for Medical Research (ICMR) , set standards for human subject research aligning with international norms like the Declaration of Helsinki and World Health Organization (WHO) guidelines. Its regulatory framework also aligns with international guidelines, including the International Conference on Harmonization (ICH) standards and regulations from bodies like the US FDA and the European Medicines Agency (EMA) , ensuring compliance with global standards.

In recent years, the Indian pharmaceutical sector has been at the forefront of technological innovation, harnessing artificial intelligence (AI), big data analytics, telemedicine, and the Internet of Medical Things (IoMT) to revolutionize healthcare delivery. PharmEasy, launched in 2015, stands as a prime example that has democratized healthcare access by seamlessly connecting patients with nearby pharmacies and diagnostic centers. Similarly, Cipla is digitizing its pharmaceutical sales approach by equipping medical representatives with iPads for e-detailing. This digital transformation enhances sales effectiveness via streamlined communication and interactive engagement with healthcare providers. This wave of innovation is supported by initiatives like the Scheme for Promotion of Research and Innovation in the Pharma MedTech Sector (PRIP) , launched in 2023.

Global Interest Supports the Indian Pharma Sector

The Indian pharmaceutical sector attracts significant foreign direct investment (FDI) due to liberalized policies, allowing up to 100% FDI for Greenfield projects and up to 74% for Brownfield ventures. Since April 2000, the sector has drawn around $22.52 billion in FDI equity inflows, supported by over 10,000 Pradhan Mantri Bhartiya Janaushadhi Kendras nationwide. Major global players such as AstraZeneca, Dr. Reddy’s, and Pfizer have heavily invested in India’s pharmaceutical industry, leveraging its manufacturing and regulatory strengths.

Hence, this sector is set for significant growth in the next decade, driven by its role in global trade and compliance with GMP standards from WHO and USFDA. As a leading producer of generics, India expects around 912% increase in medicine spending over the next five years, placing it among the top global markets. Growth will focus on chronic therapies like cardiovascular and anti-cancer treatments. Besides, pharma companies will adopt FMCG-like strategies, manage diverse channels, and leverage the influence of pharmacists and patient empowerment. Government initiatives and expanding access to low-cost generics will further support this growth.

[walkwatertalentadvisors]

India’s API Industry Manufacturing Leadership Talent 2024

API Industry in India

The Active Pharmaceutical Ingredient (or API) industry is a crucial segment of the Indian pharma industry (which is anticipated to reach USD 65 billion by 2024) and contributes to around 35 per cent of the pharma market. India is the 3rd largest producer of APIs accounting for an 8 per cent share of the Global API Industry. 500+ different APIs are manufactured in India, and it contributes 57 per cent of APIs to the prequalified list of the WHO.

The growing antagonism between the West and China has also pushed the global pharma majors to source more from countries other than China. India’s emergence as the alternate source of bulk drugs has been quite remarkable.

To capitalize on its API potential, India is building a holistic and conducive ecosystem. In 2020, the government approved INR 6,940 crore for a production-linked incentive (PLI) scheme for the promotion of domestic manufacturing of Key Starting Materials (KSMs) / Drug Intermediaries (DIs), and APIs.

Over the next several years, the Indian API market is anticipated to increase at a CAGR of 13.7 per cent. The Indian API space has become lucrative for several investors and venture capitalists. India’s robust domestic market, advanced chemical industry, skilled workforce, stringent quality and manufacturing standards, and low costs (about 40 per cent less than that in the West) for setting up and operating a modern plant give an added advantage.

Consolidation in the API Industry

Strategic M&A and PE / VC investments driving consolidation in the API industry

As per a report by EY, PE/VC investments in India’s Pharma and life sciences industry have demonstrated an impressive CAGR of 24% over the last 5 years. Since 2022, the Indian Pharma and Healthcare sector has witnessed cumulative M&A deal value of USD 15 billion.

Interestingly, a big chunk of these investments have moved to the API sector where Private Equity players / asset management firms have pursued the strategy of driving consolidation through M&As, strategic investments in API companies and building API platforms. The industry has seen emergence of several large PE owned API platform companies.

Some of these platform companies include Advent International led Cohance Lifesciences / Suven Pharma, PAG & CX Partners led Sekhmet Pharmaventures, and Carlyle backed Viyash Lifesciences and Sequent Scientific (Animal API manufacturer).  In addition to the PE action, the sector continues to see consolidation and divestment, the recent example being the acquisition of Glenmark Lifesciences by Nirma Industries.

Scope of the Study

The API industry continues to see robust action in the Leadership hiring space. Particularly in the Manufacturing function, while demand for senior leadership talent continues to grow, their availability is increasingly becoming less. Adding to this demand supply gap, we have also seen challenges related to increased compensation levels and age profile of senior leadership talent.

This report was put together by WalkWater Talent Advisors after an exhaustive study of manufacturing leadership talent in the API industry. The reports seeks to understand some of the key trends and talent insights which are driving leadership hiring in this function.

Research Methodology

Definitions

Site Heads – Manufacturing leaders who are responsible for all operations in a manufacturing Site.

Cluster Heads – Manufacturing leaders who are responsible for driving manufacturing operations across a cluster of API Sites / Plants.

Chief Operating Officers (COO)– Leaders who are responsible for driving overall manufacturing operations across all manufacturing sites in an organization. They are reported into by Clusters Heads / multiple plant heads.

API – API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that causes an intended medical effect.

Captive Organizations – Firms that manufacturing APIs for their in-house production needs

Merchant Organizations – Firms that manufacture APIs to be sold to third party customers

Key findings

Inferences: One of the startling findings of our study is that there is no diversity talent across leadership levels in the manufacturing function across all company’s studied in this report. In an era of Diversity, Equity and Inclusion, this finding is a call out to all key decision makers / influencers  of this industry to urgently address this issue so that there can be better representation of diversity and a more inclusive approach to talent growth in this industry.

Inferences: Given the highly technical nature of the manufacturing roles, it is no surprise that 95% of the leadership talent pool are Chemical engineers / Chemistry Graduates by education. More over, 41% of this talent pool are full time Masters / Doctorates.

Inferences: There are 3 emerging geographic talent clusters for API manufacturing leadership talent in India – AP + Telangana is by far the largest cluster, followed by Maharashtra and Gujarat. These 3 clusters make up more than 82% of the available leadership talent in the manufacturing function and one can expect that these 3 clusters will continue to attract a major portion of planned investments in this sector.

Inferences: A 40% churn in the leadership talent is significant in any industry and given the action happening in this industry, we expect this trend to continue to grow for the next few years. More importantly, as the industry sees continued investments leading to the manufacturing networks becoming more complex, the industry has beefed up hiring of COO candidates to provide leadership and strategic direction to manage the growth of the manufacturing operations.

Inferences: The findings suggest manufacturing leadership talent is ageing in this industry. Further as the demand supply gap widens, the industry will need to focus on better talent management strategies so that younger talent can be groomed to take up leadership responsibilities faster and more effectively. To make up the shortage of leadership talent in the near term, companies are giving extensions to existing talent beyond their retirement age. 

Inferences: Given the increased demand of leadership talent in the manufacturing function, compensation levels have increased in this industry and surprisingly the median CTC across levels are today comparable to CTC trends in FMCG industry for similar talent.

Cost to company (CTC) here means annual fixed + variable compensation. For critical talent, most companies also offer wealth creation opportunity through long term incentives / esops / stocks – this component is not part of the CTC figures above.

About Lead Authors

Rahul Shah Co-Founder & Director

Rahul brings 25+ years of industry experience, out of which, he has spent more than 22 years in the Executive Search industry. Post MBA, he worked for close to 3 years with Usha Martin’s Alloy & Steels business and then moved to the Executive Search industry with ABC Consultants. He spent more than 9 years with ABC Consultants and in his last role, he was an Executive Director responsible for running the Bangalore office, the 3rd largest office by revenues. As Co-Founder of WalkWater, he personally leads Senior Searches across sectors, with a sectoral specialization in the Consumer, Pharma and Industrial sectors. He is an Instrumentation Engineer from Bangalore University and has completed his MBA from XIM, Bhubaneswar. He is certified in Personal Profile Analysis from Thomas International. Outside work, he is a biker and loves to travel and watch movies.

Prakash HS Senior Vice President | Pharma & Lifesciences

Prakash brings 22+ years of work experience of which 6 years has been in Marketing and Sales in the Pharma industry and the last 16 years in the Executive Search industry with focus on leadership and niche hiring for the Pharma, Healthcare & Lifesciences segments. He started his career in Pharma sales, subsequently joined Pfizer and had a successful stint there. Post Pfizer, he shifted to the Executive Search industry with stints in market leading companies like ABC Consultants and Korn Ferry. At WalkWater, Prakash is the sector specialist for the Pharma, Healthcare and Life science industries and has advised several MNCs and large Indian Pharma companies on critical searches and talent advisory engagements.

[dezincounsulting]

Indian Pharmaceutical Industry | Dezin Consulting

Explore the evolution and high demand for effective leadership in the Indian Pharmaceutical Industry in Dezin Consulting's latest blog. Gain insights into the industry's growth and challenges at https://www.dezin.co.in/blog-14-indian-pharmaceutical-industry-evolution-high-demand-for-better-leaders. Stay informed about the dynamic landscape shaping the future of this crucial sector.

Indian pharmaceutical industry has undergone significant reform in the last few years. The technological advances, the pandemic, and the overall revamping of the healthcare landscape have created a new surge in the industry- to evolve and do better. Quality leadership is integral to navigating the changing landscape, and the right time to start working on your leadership creed is now.

Quality leadership is the key to sustainable existence in the pharmaceutical industry in India. With advanced leadership development programs, a pharma company can hone its human assets and tap into the opportunities knocking on the doors. As per research by McKinsey, 30 percent of the leaders from top pharmaceutical companies across the world have participated in one or more leadership programs post-pandemic.

Indian pharmaceutical industry: where is the road headed to

The need for quality healthcare and a proactive approach to life science is critical. The industry is changing in terms of innovation of new drugs, rising competition as well as the quality of people joining the industry to explore their chances. If you want your organization to succeed and have quality talent, you must work on their skills and make them better leaders.

So, what are the major changes that the industry has undergone or is expecting:

Global recognition

Indian pharmaceutical industry is gaining global recognition. Although it has been a major contributor to the global medical industry, the Atmanirbhar campaign, and further established it as a manufacturer of quality medicines with heavily unexplored potential.

India provides for more than 60% of the global demand for different vaccines as well as ARV drug supplies. 

It handles more than 30% of the total medicine supply of UNICEF across the globe.

Over 60-80% of the UN total medicine sales is provided by India.

Indian medicines are also registered under the WHO’s pre-qualified list- 57% of APIs and 69% of FPP (Finished Pharma Products) 

New government initiatives

There are several government policies and acts that work in the favor of the pharma industry in India. The Patent Act 1970, The Drug Policy 1978, Hatch-Waxman Act 1984, and the 1991 Economic Reform are to name a few. The latest schemes launched by the government including the Production Linked Incentive (PLI) Scheme and the scheme on Promotion of Bulk Drug Parks have further promoted the Indian pharma capabilities and established India in the list of top leaders.

Indian pharmaceutical industry demands better leadership

As the industry continues to emerge, the need for quality leadership has become the key to sustainability and profitability. As great leaders, employees would enhance their careers while contributing to the success of your organization.

A true leader would help with an overall organizational reform, establishing the company in alignment with the globally evolving industry parameters. With the increase in functional and organizational capabilities, organizations would be able to induce overall development and thus gain profitability.

A credible leadership coaching agency offers enhanced leadership programs as per the structure of the companies which help them align their goals with the company’s objectives.

[mv-altios]

India’s Life Sciences Industry Set to Boom in the Near Future

The Life Sciences sector in #india is currently witnessing impressive growth and a broadening range of capabilities throughout the industry's value chain.

India has emerged as a significant exporter of life sciences and #pharmaceutical products, serving over 200 countries through foreign pharma companies. India supplies more than 50% of Africa's generic medicine requirements, around 40% of the demand for generic medicine in the US, and nearly 25% of all medicinal products in the UK.

In the fiscal year 2021-22, the Average Index of Industrial Production for the manufacturing of life science, medicinal, chemical, and botanical products in India stood at 221.6, reflecting a growth rate of 1.3%. With its skilled labor force and cost advantages, India has become an appealing destination for research, development, and #manufacturing facilities in the #lifesciences industry.

Government initiatives, including incentivization plans and budget allocations, further bolster the industry. The Production Linked Incentive (#pli) scheme is projected to generate incremental #sales of USD 37.09 billion within six years.

At M+V Altios, our team of industry experts, led by market expansion expert Deepmala Datta and Madhav Raina-Thapan, is dedicated to supporting life sciences companies in India. We can help you seize growth opportunities, navigate challenges, and establish a strong presence in the Indian market.

[mediwinpharma]

The New Leap of Indian Pharma Export in FY23

Introduction

Pharma companies have seen significant growth in the industry, and technological advancement and growing demand are the main factors for this growth. The new rules are helping the industry, and new technology is making it easier to sell medicine. Indian medicine is known for being of good quality and for being innovative, so the future looks good for Indian medicine sales.

This blog will explore the growth of medicine export from India, the factors for the growth of top Indian pharma export companies, and their impact on the economy.

Factors Contributing to the Growth of the Pharmaceutical Industry in India

Here are some pointers explaining the factors briefly.

1. Government Initiatives to Boost Pharma Export

Some initiatives taken by the government to boost the pharma export are as follows:

In March 2022, the government announced the strengthening of the pharmaceutical industry (SPI) scheme with a total budget of 500 crores for FY 2021-22 to FY 2025-26.

After a hiatus, India resumed deliveries of COVID-19 shots to the COVAX program in November-December

In November 2021, Prime Minister Narendra Modi launched the inaugural Global Innovation Summit for the pharmaceutical industry. The summit will consist of 12 sessions with more than 40 speakers from both national and international backgrounds discussing various topics such as regulations, financing for innovation, and infrastructure for innovation.

The Department of Pharmaceuticals has launched a PLI (Production Linked Incentive) scheme to promote domestic manufacturing of essential bulk drugs to achieve self-sufficiency and reduce the country’s dependence on imports. The total cost of the scheme will be 6,940 crores and will be implemented between FY21 and FY30.

2. Investment in R&D and innovation

Research and development (R&D) are important in every industry. It is particularly essential in the biopharmaceutical research sector. It helps to save lives and increase profits. Developing new vaccinations and therapies is becoming increasingly difficult. Reliable R&D services can help pharmaceutical enterprises follow manufacturing methods, leading to the creation of numerous new medications.

In 2015, the industry spent Rs. 6,02,388 crore on R&D for novel medicines. The approval process for these export medicines can be lengthy, but the number of successful approvals determines the businesses’ ability to recoup their investment and profit.

3. Globalization

When India opened its socialist economy and began trading globally, big pharma exporters from the US and Europe entered the Indian market. They set up cheaper and more efficient production facilities offshore to reduce costs and expand their operations. This created opportunities for small-scale industries to grow their products. The entry of big pharma companies into the Indian market allowed smaller businesses to expand, create more opportunities, and export pharmaceutical products worldwide.

4. Quality and Compliance

Quality and compliance are crucial to India’s growth in the pharmaceutical industry. With the rising pharmaceutical sector, all companies must follow strict quality standards to ensure their products are safe. This led to more investment in research and development and better manufacturing processes.

By applying such factors, India’s pharmaceutical industry is recognized for producing high-quality products that follow international standards, which attracts more business and investment globally. This way, India can export medicines in a more accessible way.

Impact of the Growth of Pharmaceutical Companies on the Economy

The growth of India has had a significant impact on the country’s economy. Here are some ways in which the pharma exporters have contributed to the economy:

1. Improved Healthcare Access

The pharmaceutical industry in India has been growing rapidly. The government is helping more people afford healthcare and medicine by making them cheaper. India needs to have its medical industry so it doesn’t depend too much on China. Therefore, India is making plans to produce more medicine inside the country.

These plans are called “production-linked incentive” (PLI) schemes. The PLI schemes give money to Indian companies to help them make more medicine and medical equipment. The PLI schemes have been working well so far. In the last two years, nearly Rs. 16,435 crore has been given to 55 companies to help them make medicine.

2. Job Creation and Economic Benefits

A pharma exporter plays an important role in the Indian economy. Top Indian pharma export companies employ around 2.7 million people directly to the firm. It also creates employment through the supply chain.

The pharmaceutical sector also contributes to the country’s economic growth by generating revenue and promoting medicine export from India, a leading pharma exporter.

The government of India took several initiatives to promote the sector, including allocating funds for research and development, boosting domestic manufacturing, and promoting innovation to increase medicine export from India.

3. Increased Revenue and Growth for the Indian Pharma Industry

The pharmaceutical industry in India is a significant player in the global market. Here are some reasons why:

The Indian pharmaceutical industry is ranking third in production by volume and 14th by value.

From April 2000 and June 2022, foreign investment in India’s drugs and pharmaceutical industry was around $19.90 billion.

Cipla and Drugs for Neglected Diseases initiative (DNDi) teamed up to launch a new medicine in June 2022 to treat HIV in children in South Africa.

The Union Cabinet has approved FDI up to 100% under the automatic route for manufacturing medical devices subject to certain conditions.

In August 2021, Uniza Group signed an agreement with Lysulin Inc. to introduce Lysulin, a nutritional product for Indian consumers.

How can Pharmaceutical Companies Leverage the New Leap?

Pharmaceutical companies can leverage the new leap in various ways to expand their business and make a mark in the global market. Here are a few pointers:

1. Maximize Efficiency

Production efficiency refers to achieving output goals with minimal input. Collecting data from various areas makes it possible to identify improvement areas. Automation can also reduce the manual input, time, and resources required to complete tasks.

Efficiency can also be improved by the convergence of information technology (IT) and operational technology (OT) through the use of Industrial Internet of Things (IIoT) technology. It allows for data collected from production to inform business decisions. Efficient communication between IT and OT is facilitated by a common structure for data exchange.

2. Improve Industrial Security

Pharmaceutical companies can face cyberattacks and security threats, which can cause them to hesitate to adopt new technologies that could improve productivity. However, implementing these technologies while safeguarding against security risks can provide a competitive advantage.

Having a strong cybersecurity system and using technologies with top-notch built-in security features is crucial. COPA-DATA has received a certificate of conformity from TÜV SÜD, which verifies compliance with the industrial IT security standards outlined in the ISA/IEC 62443-4-1:2018 guidelines.

3. Simplify Operation Workflows

The pharmaceutical industry has strict quality requirements at every step of the process. The common batch process can be beneficial, but it also means that one error can lead to a ruined batch, wasted resources, and potentially serious consequences. Effective batch control is crucial to avoid these negative scenarios.

Pharmaceutical manufacturers must collect and manage process data to ensure the quality of exported pharmaceutical products. However, relying on paper documentation can lead to errors. Automating data collection with mobile devices can improve efficiency and reduce the likelihood of mistakes. This way, you can export medicines without committing errors.

4. Better Production

Efficiency in pharmaceutical manufacturing can also be improved by increasing machinery life and uptime. Equipment breakdowns and underperformance can cost companies money in terms of repairs, lost production time, and damaged batches of products. Investing in high-quality equipment and implementing an effective maintenance program can help export pharmaceutical products more efficiently.

Predictive maintenance programs can be more efficient than fixed or reactive schedules because they allow companies to forecast when maintenance is needed based on data collected from the sensors. This helps companies avoid unnecessary maintenance work and detect signs of future failures before they cause downtime or high repair costs.

Conclusion

Based on the information, it can be expected that the Indian pharmaceutical company will witness a considerable surge in export growth during FY23. The pharmaceutical company’s growth can be attributed to healthcare expansion and growing research and development. By doing all this, India is now a global lead player that export pharmaceutical products to all nations.

Mediwin Phayrmaceuticals has a unique opportunity to leverage its commitment to quality and innovation to emerge as a dominant player in the industry. Mediwin will capture a substantial portion of the expanding global market and has the potential to become one of the top Indian pharma export companies in the global market.

Source link

[newswireml]

Electronics manufacturing, auto get best of Budget spending on PLI scheme#Electronics #manufacturing #auto #Budget #spending #PLI #scheme

Union Budget 2023-24 has earmarked Rs 8,083 crore for production linked incentive schemes (PLI), a bulk of the money going for large-scale electronics manufacturing, which includes mobile devices, pharma, auto and auto components, and food processing. Eight of the 14 PLIs covered in these segments account for 99 per cent of the money the Budget earmarked for the schemes across government…

[shlipayadavblog]

Expand PLI scheme for pharma to make it research-linked, says industry

Indian pharma industry captains feel that the current production linked incentive (PLI) scheme for the pharmaceutical industry can be expanded to link it to research, and more specifically for research in biologics and biosimilars.

Speaking at BioAsia 2022, Kiran Mazumdar Shaw, executive chairperson, Biocon Group, said that there needs to be a different PLI scheme that needs to focus on the emerging opportunities for Indian pharma. “As a nation we need to start moving towards large molecules of biologics. There is a huge growing interest in combination immuno-therapies. Can we leap-frog? The PLI scheme was far too skewed far too much towards generic drugs. There should have been a much greater allocation for biologics, biosimilars, cell and gene therapies etc, which did not happen,” Shaw explained.

In fact she cited the example of Biocon to say, “We could not be eligible for category A companies because we did not have that many ANDAs. So, we got a very small amount.”

The Rs 15,000 crore PLI scheme announced by the Centre has three categories of companies – category A (FY20 global manufacturing revenue of pharma goods more than equal to Rs 5000 crore), category B (between Rs 500 crore to Rs 5000 crore) and category C (revenue less than Rs 500 crore). The quantum of incentives vary for the three groups – Rs 11,000 crore (Group A), Rs 2250 crore (Group B) and Rs 1750 crore (Group C).

So far 55 drug manufacturers have been selected under the PLI scheme.

[technomoz]

55 pharma companies qualify for ₹15,000-crore PLI scheme

55 pharma companies qualify for ₹15,000-crore PLI scheme

Up to 55 companies are eligible for the Production Linked Incentive (PLI) scheme for the pharmaceutical sector. The list includes big players such as Sun Pharmaceuticals, Cipla, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Wockhardt, Biocon, Biologic E, Panacea Biotech, Torrent Pharma, Aurobindo Pharma, Intas Pharma, Natco Pharma and Lupine. The scheme will provide financial incentives of…

[hindinewsnowfan]

फार्मा सेक्टर को आत्मनिर्भर बनाने के लिए मोदी सरकार ने जारी किए 4 नए गाइडलाइन

फार्मा सेक्टर को आत्मनिर्भर बनाने के लिए मोदी सरकार ने जारी किए 4 नए गाइडलाइन

[ad_1]

घरेलू मैन्युफैक्चरिंग को बढ़ावा देने के लिए सरकार ने जारी किए दिशानिर्देश सरकार ने सोमवार को देश में बल्क ड्रग (Bulk Drug) के घरेलू विनिर्माण को बढ़ावा देनेऔर मेडिकल डिवाइस पार्कों (medical device parks) के विकास के लिए चार योजनाओं के…